Clinical Scorecard: Initiation Timing of Antidiabetic Medications and Its Impact on Cardiovascular Events and Mortality Risk
At a Glance
Category
Detail
Condition
Type 2 Diabetes (T2D)
Key Mechanisms
Chronic hyperglycemia increases cardiovascular disease and mortality risk; early glycemic control can reduce major adverse cardiovascular events (MACE) and mortality.
Target Population
Adults aged ≥18 years with newly diagnosed T2D.
Care Setting
Retrospective cohort study using health screening data and national health insurance claims.
Key Highlights
Intensive glycemic control in early diabetes can reduce MACE and mortality.
Early initiation of antidiabetic medications (ADM) is recommended upon diagnosis.
The study analyzed the impact of ADM initiation timing on cardiovascular outcomes.
Guideline-Based Recommendations
Diagnosis
Regular health screenings are essential for timely diagnosis of T2D.
Management
Prompt pharmacologic intervention is advocated upon diagnosis of T2D.
Monitoring & Follow-up
Monitor glycemic status and cardiovascular health in individuals with T2D.
Risks
Delays in diagnosis and treatment can lead to increased cardiovascular risks.
Patient & Prescribing Data
Individuals with prediabetes and newly diagnosed T2D.
Various ADM options include metformin, SGLT-2 inhibitors, GLP-1 receptor agonists, and others.
Clinical Best Practices
Initiate ADM within 3 months of T2D diagnosis to reduce cardiovascular risks.
Utilize comprehensive health checkups for early identification of T2D.
by Hwa Yeon Ko, Ju-Young Shin, Kyungyeon Jung, Sungho Bea, Bin Hong, Yunha Noh, Jae Hyun Bae, Soo Heon Kwak, Young Min Cho, Ga-young Lim, Jiin Ahn, Seungho Ryu, Ju Hwan Kim, Yoosoo Chang
Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.
Across 3 studies, higher fertility was associated with greater preference for luxury when it was visible, personally relevant, and potentially noticeable to others.
